The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy.
dc.contributor.author | Treacy, Maxwell P | |
dc.contributor.author | Hurst, Tara P | |
dc.date.accessioned | 2013-04-24T11:45:26Z | |
dc.date.available | 2013-04-24T11:45:26Z | |
dc.date.issued | 2012-09 | |
dc.identifier.citation | The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy. 2012, 12:46 BMC Ophthalmol | en_GB |
dc.identifier.issn | 1471-2415 | |
dc.identifier.pmid | 22937835 | |
dc.identifier.doi | 10.1186/1471-2415-12-46 | |
dc.identifier.uri | http://hdl.handle.net/10147/283772 | |
dc.description.abstract | Systemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy. In this paper, we provide a rationale for the use of these therapeutics as intraocular agents. In addition, we introduce the peroxisome proliferator-activated receptors and describe their functions in response to the drugs. | |
dc.language.iso | en | en |
dc.relation.url | http://www.biomedcentral.com/content/pdf/1471-2415-12-46.pdf | en_GB |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532122/pdf/1471-2415-12-46.pdf | en_GB |
dc.rights | Archived with thanks to BMC ophthalmology | en_GB |
dc.subject.mesh | Diabetic Retinopathy | |
dc.subject.mesh | Eye | |
dc.subject.mesh | Fenofibrate | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Hypolipidemic Agents | |
dc.subject.mesh | Injections | |
dc.subject.mesh | PPAR alpha | |
dc.subject.mesh | Treatment Outcome | |
dc.title | The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy. | en_GB |
dc.type | Article | en |
dc.contributor.department | Royal Victoria Eye and Ear Hospital, Adelaide Road, Dublin 2, Dublin, Ireland. max@treacy.ie | en_GB |
dc.identifier.journal | BMC ophthalmology | en_GB |
dc.description.province | Leinster | en |
refterms.dateFOA | 2023-09-13T16:11:33Z | |
html.description.abstract | Systemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy. In this paper, we provide a rationale for the use of these therapeutics as intraocular agents. In addition, we introduce the peroxisome proliferator-activated receptors and describe their functions in response to the drugs. |